NCT06851663 Trop2-targeted immunoPET Imaging of Solid Tumors
| NCT ID | NCT06851663 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | RenJi Hospital |
| Condition | Solid Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2024-12-23 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 400 participants in total. It began in 2024-12-23 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) will be evaluated.
Eligibility Criteria
Inclusion Criteria: * Aged 18-75 year-old and of either sex * Histologically confirmed diagnosis of solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) or suspected solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) by diagnostic imaging; * Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol. Exclusion Criteria: * Pregnancy； * Severe hepatic and renal insufficiency; * Allergic to single-domain antibody radiopharmaceuticals.
Contact & Investigator
Jianjun Liu, Ph.D. & M.D.
STUDY CHAIR
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Frequently Asked Questions
Who can join the NCT06851663 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Solid Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06851663 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06851663 currently recruiting?
Yes, NCT06851663 is actively recruiting participants. Contact the research team at wwei@shsmu.edu.cn for enrollment information.
Where is the NCT06851663 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06851663 clinical trial?
NCT06851663 is sponsored by RenJi Hospital. The principal investigator is Jianjun Liu, Ph.D. & M.D. at Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University. The trial plans to enroll 400 participants.